AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36790846 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention consisting of sending messages through a multimedia messaging service with food education for 12 weeks
Number of subjects: 0
Study 36790846 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 0
Study 36790849 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36790852 — intervention group
Group type: EXPERIMENTAL
Intervention: VR (Virtual Reality)
Number of subjects: 126
Study 36790852 — intervention group
Group type: COMPARATOR
Intervention: MEOPA (mixture of nitrous oxide/oxygen)
Number of subjects: 126
Study 36790852 — intervention group
Group type: EXPERIMENTAL
Intervention: VR
Number of subjects: 126
Study 36790875 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose Management Indicator (GMI)
Number of subjects: 0
Study 36790875 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated Hemoglobin (HbA1c)
Number of subjects: 0
Study 36790881 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36790946 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic Breathing (YB) via app for 12 weeks
Number of subjects: 20
Study 36790946 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC) via app for 12 weeks
Number of subjects: 20
Study 36791089 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-applied treatment for rat phobia supported by a Virtual Therapy Assistant (VTA)
Number of subjects: 45
Study 36791089 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 45
Study 36791161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-RSV preF protein vaccine
Number of subjects: 5782
Study 36791161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5782
Study 36791160 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Number of subjects: 24966
Study 36791160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24966
Study 36791166 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of radiotherapy
Number of subjects: 0
Study 36791162 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (3-μg dose)
Number of subjects: 3013
Study 36791162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3013
Study 36791280 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 25237
Study 36791280 — intervention group
Group type: COMPARATOR
Intervention: Epoetin beta
Number of subjects: 25237
Study 36791280 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 25237
Study 36791280 — intervention group
Group type: COMPARATOR
Intervention: Methoxy polyethylene glycol-epoetin beta
Number of subjects: 25237
Study 36791280 — intervention group
Group type: COMPARATOR
Intervention: Biosimilar epoetin
Number of subjects: 25237
Study 36791280 — intervention group
Group type: COMPARATOR
Intervention: Biosimilar darbepoetin alfa
Number of subjects: 25237
Study 36791586 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 36791586 — intervention group
Group type: COMPARATOR
Intervention: Comfort-directed care
Number of subjects: 0
Study 36791622 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-phase rhinomanometry
Number of subjects: 139
Study 36791622 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated hypopnea apnea ratio
Number of subjects: 139
Study 36791792 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment
Number of subjects: 0
Study 36791792 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related dose adjustments
Number of subjects: 0
Study 36791792 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate (GFR) adjustments
Number of subjects: 0
Study 36791845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin + Roxithromycin
Number of subjects: 124
Study 36791845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime + Roxithromycin
Number of subjects: 124
Study 36791987 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcast education (links to 7 labor-related podcast episodes)
Number of subjects: 201
Study 36791987 — intervention group
Group type: COMPARATOR
Intervention: Control (usual education)
Number of subjects: 201
Study 36791986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (40 mL of 0.25% bupivacaine)
Number of subjects: 79
Study 36791986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (40 mL of normal saline solution)
Number of subjects: 79
Study 36791986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 79
Study 36791986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 36792107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) Q4W
Number of subjects: 932
Study 36792107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) Q2W
Number of subjects: 932
Study 36792107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (from COAST-X)
Number of subjects: 932
Study 36792266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound renal denervation
Number of subjects: 0
Study 36792266 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency renal denervation
Number of subjects: 0
Study 36792325 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care + Implantable Loop Recorder (ILR) + Holter monitor
Number of subjects: 200
Study 36792325 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 200
Study 36792325 — intervention group
Group type: EXPERIMENTAL
Intervention: ILR-arm
Number of subjects: 200
Study 36792323 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (>2 Gy/fraction)
Number of subjects: 0
Study 36792323 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (1.8-2 Gy/fraction)
Number of subjects: 0
Study 36792333 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron and folic acid (IFA) supplementation
Number of subjects: 4500
Study 36792333 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multiple micronutrient supplements (MMSs)
Number of subjects: 4500
Study 36792333 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 4500
Study 36792333 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly IFA and Daily MMSs
Number of subjects: 4500
Study 36792337 — intervention group
Group type: EXPERIMENTAL
Intervention: tildrakizumab
Number of subjects: 500
Study 36792338 — intervention group
Group type: EXPERIMENTAL
Intervention: Early breastfeeding initiation
Number of subjects: 1114
Study 36792338 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding to 6 months
Number of subjects: 1114
Study 36792338 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight regain by 2 weeks
Number of subjects: 1114
Study 36792338 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth outcomes at 6 months
Number of subjects: 1114
Study 36792338 — intervention group
Group type: COMPARATOR
Intervention: Preterm-SGA vs Preterm-AGA
Number of subjects: 1114
Study 36792338 — intervention group
Group type: COMPARATOR
Intervention: Term-SGA vs Preterm-AGA
Number of subjects: 1114
Study 36792338 — intervention group
Group type: COMPARATOR
Intervention: Not regaining birthweight by 2 weeks vs regaining
Number of subjects: 1114
Study 36792367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 0
Study 36792378 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke participants
Number of subjects: 71
Study 36792378 — intervention group
Group type: COMPARATOR
Intervention: Stroke-free controls
Number of subjects: 71
Study 36792639 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% isobaric bupivacaine (3 ml)
Number of subjects: 111
Study 36792639 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine (3 ml)
Number of subjects: 111
Study 36792639 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine (3 ml)
Number of subjects: 111
Study 36792650 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term family-centered workshop (six 2-h sessions for six weeks)
Number of subjects: 101
Study 36792782 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure device
Number of subjects: 214
Study 36792782 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 214
Study 36792805 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisavanbulin administered as a 48-hour intravenous infusion at the recommended Phase 2 dose (RP2D) of 70 mg/m²
Number of subjects: 0
Study 36792844 — intervention group
Group type: EXPERIMENTAL
Intervention: Acromegaly Symptom Diary (ASD)
Number of subjects: 60
Study 36792998 — intervention group
Group type: EXPERIMENTAL
Intervention: T50 test
Number of subjects: 776
Study 36793000 — intervention group
Group type: COMPARATOR
Intervention: ESPB (20 ml 0.25% bupivacaine)
Number of subjects: 60
Study 36793000 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPB + DEX (19 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 µg/kg)
Number of subjects: 60
Study 36793000 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPB + DEX
Number of subjects: 60
Study 36793044 — intervention group
Group type: EXPERIMENTAL
Intervention: Run Daddy Run intervention
Number of subjects: 98
Study 36793044 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 36793058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Grade (NG) label on beverages
Number of subjects: 138
Study 36793058 — intervention group
Group type: COMPARATOR
Intervention: Control with Healthier Choice Symbol (HCS) logos
Number of subjects: 138
Study 36793089 — intervention group
Group type: EXPERIMENTAL
Intervention: Women > 50 years
Number of subjects: 322
Study 36793089 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri- and menopausal women
Number of subjects: 322
Study 36793089 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 322
Study 36793089 — intervention group
Group type: COMPARATOR
Intervention: All subjects
Number of subjects: 322
Study 36793092 — intervention group
Group type: EXPERIMENTAL
Intervention: Niclosamide plus ramipril
Number of subjects: 60
Study 36793092 — intervention group
Group type: COMPARATOR
Intervention: Ramipril only (Control)
Number of subjects: 60
Study 36793095 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T therapy in Ph-like ALL
Number of subjects: 91
Study 36793095 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T therapy in Ph+ ALL
Number of subjects: 91
Study 36793095 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T therapy in other B-ALL
Number of subjects: 91
Study 36793105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 192
Study 36793105 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 192
Study 36793105 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss plus Mediterranean diet
Number of subjects: 192
Study 36793105 — intervention group
Group type: COMPARATOR
Intervention: Typical diet controls
Number of subjects: 192
Study 36793105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet, weight loss, weight loss plus Mediterranean diet
Number of subjects: 192
Study 36793118 — intervention group
Group type: EXPERIMENTAL
Intervention: baricitinib 4 mg per day + hydroxychloroquine (HCQ) 400 mg per day
Number of subjects: 87
Study 36793118 — intervention group
Group type: COMPARATOR
Intervention: hydroxychloroquine (HCQ) 400 mg per day alone
Number of subjects: 87
Study 36793118 — intervention group
Group type: EXPERIMENTAL
Intervention: baricitinib + HCQ
Number of subjects: 87
Study 36793118 — intervention group
Group type: COMPARATOR
Intervention: HCQ
Number of subjects: 87
Study 36793385 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0
Study 36793385 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 36793451 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-targeted proteomics assessment of amyloid-beta peptides
Number of subjects: 719
Study 36793546 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula (eHF-C)
Number of subjects: 76
Study 36793546 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed whey protein formula (eHF-W)
Number of subjects: 76
Study 36793800 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised machine learning (k-means; km3d) modeling of clinical and functional disease measures
Number of subjects: 0
Study 36794283 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 15 mg once daily, either as monotherapy after switching from MTX or in combination with stable background conventional synthetic DMARDs (csDMARDs)
Number of subjects: 0
Study 36794283 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (UPA) 15 mg once daily
Number of subjects: 0
Study 36794283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36794354 — intervention group
Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel) at doses of 150, 300, or 450 × 10^6 CAR T cells
Number of subjects: 127
Study 36794691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermuscular (IM) S-ICD implantation
Number of subjects: 290
Study 36794691 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SC) S-ICD implantation
Number of subjects: 290
Study 36794731 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted strategies implemented during Months 7-13 to improve recruitment.
Number of subjects: 60
Study 36794731 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies based on Consolidated Framework for Implementation Research.
Number of subjects: 60
Study 36794816 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk oligosaccharides
Number of subjects: 0
Study 36794963 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerade® 500 μg
Number of subjects: 12
Study 36794963 — intervention group
Group type: COMPARATOR
Intervention: Emerade® 300 μg
Number of subjects: 12
Study 36794963 — intervention group
Group type: COMPARATOR
Intervention: Epipen® 0.3 mg
Number of subjects: 12
Study 36795232 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment at week 3
Number of subjects: 148
Study 36795232 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment at week 12
Number of subjects: 148
Study 36795232 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment
Number of subjects: 148
Study 36795303 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured clinical pharmacist-delivered intervention (medication reconciliation and counselling at discharge, and two follow-up sessions at 4 and 8 weeks post-discharge)
Number of subjects: 373
Study 36795303 — intervention group
Group type: COMPARATOR
Intervention: Usual care (general usual care at discharge by clinical pharmacists)
Number of subjects: 373
Study 36795303 — intervention group
Group type: COMPARATOR
Intervention: Control group (discharged during weekends or after clinical pharmacists' working hours)
Number of subjects: 373
Study 36795388 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with carboplatin plus nab-paclitaxel (IMpower130)
Number of subjects: 2503
Study 36795388 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with carboplatin or cisplatin plus pemetrexed (IMpower132)
Number of subjects: 2503
Study 36795388 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus bevacizumab plus carboplatin and paclitaxel (IMpower150)
Number of subjects: 2503
Study 36795388 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab-containing regimens
Number of subjects: 2503
Study 36795388 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control)
Number of subjects: 2503
Study 36795465 — intervention group
Group type: EXPERIMENTAL
Intervention: JomPrEP smartphone app
Number of subjects: 50
Study 36795510 — intervention group
Group type: EXPERIMENTAL
Intervention: Roll-over technique (ROG)
Number of subjects: 62
Study 36795510 — intervention group
Group type: COMPARATOR
Intervention: Standard paracentesis (SPG)
Number of subjects: 62
Study 36795619 — intervention group
Group type: EXPERIMENTAL
Intervention: ATA risk estimation
Number of subjects: 4773
Study 36795619 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree model
Number of subjects: 4773
Study 36795619 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of additional variables
Number of subjects: 4773
Study 36795707 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent-mediated diabetes intervention
Number of subjects: 160
Study 36795707 — intervention group
Group type: COMPARATOR
Intervention: Leadership and life skills-focused control curriculum
Number of subjects: 160
Study 36795739 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer leadership program for Grade 6/7 students, delivered through a half-day workshop and 7 x 40 minute lessons, followed by a ten-week physical literacy program (2x30 minutes sessions per week).
Number of subjects: 359
Study 36795739 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer leadership program for Grade 6/7 students.
Number of subjects: 359
Study 36795739 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (usual routines for Grade 3/4 students).
Number of subjects: 359
Study 36795763 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families-PrEP intervention; PrEP provided in electronic pillboxes; adherence measured as pillbox opened ≥80% of days.
Number of subjects: 131
Study 36795763 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families-PrEP intervention; PrEP adherence during pregnancy follow-up.
Number of subjects: 131
Study 36795763 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families-PrEP intervention; TFV-DP concentrations measured quarterly.
Number of subjects: 131
Study 36795763 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families-PrEP intervention; pregnancy outcomes.
Number of subjects: 131
Study 36795843 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide plus androgen-deprivation therapy and docetaxel
Number of subjects: 1305
Study 36795843 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus androgen-deprivation therapy and docetaxel
Number of subjects: 1305
Study 36795891 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib
Number of subjects: 405
Study 36795891 — intervention group
Group type: COMPARATOR
Intervention: Control medication
Number of subjects: 405
Study 36796016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azacitidine (CC-486) at 300 mg daily for 7 days before C1 of CHOP, and for 14 days before CHOP C2-6 plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 20
Study 36796016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azacitidine (CC-486) plus CHOP
Number of subjects: 20
Study 36796092 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial Lung Cryobiopsy
Number of subjects: 0
Study 36796092 — intervention group
Group type: COMPARATOR
Intervention: Surgical Lung Biopsy
Number of subjects: 0
Study 36796097 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36796234 — intervention group
Group type: EXPERIMENTAL
Intervention: xevinapant plus CRT
Number of subjects: 96
Study 36796234 — intervention group
Group type: COMPARATOR
Intervention: placebo plus CRT
Number of subjects: 96
Study 36796353 — intervention group
Group type: EXPERIMENTAL
Intervention: CCMDD program
Number of subjects: 390
Study 36796440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal short-chain fatty acids (SCFAs) and plasma cytokines (TNF-α)
Number of subjects: 34
Study 36796440 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal short-chain fatty acids (SCFAs) and plasma cytokines (IL-1RA)
Number of subjects: 34
Study 36796440 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary markers (including animal protein)
Number of subjects: 34
Study 36796484 — intervention group
Group type: EXPERIMENTAL
Intervention: STSP-0601 (0.01 U/kg, 0.04 U/kg, 0.08 U/kg, 0.16 U/kg, 0.32 U/kg, or 0.48 U/kg) in part A
Number of subjects: 23
Study 36796484 — intervention group
Group type: EXPERIMENTAL
Intervention: STSP-0601 (0.16 U/kg, maximum of 6 4-hourly injections) in part B
Number of subjects: 23
Study 36796484 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 23
Study 36796498 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative SABR (Stereotactic Ablative Body Radiotherapy) for early-stage breast cancer, details on dosage and duration not available.
Number of subjects: 0
Study 36796498 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study 36796573 — intervention group
Group type: EXPERIMENTAL
Intervention: vFFR guided coronary revascularization
Number of subjects: 2228
Study 36796573 — intervention group
Group type: COMPARATOR
Intervention: FFR guided coronary revascularization
Number of subjects: 2228
Study 36796574 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-video-supervised exercise (aerobic+resistance) intervention
Number of subjects: 0
Study 36796585 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon catheter
Number of subjects: 158
Study 36796623 — intervention group
Group type: EXPERIMENTAL
Intervention: Race-Based Stress and Trauma Empowerment (RBSTE)
Number of subjects: 48
Study 36796623 — intervention group
Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 48
Study 36796641 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster antenatal corticosteroids (12 mg betamethasone every 24 hours for 2 days)
Number of subjects: 194
Study 36796641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 194
Study 36796641 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster antenatal corticosteroids
Number of subjects: 194
Study 36796641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 36796647 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D optical imaging (3DO)
Number of subjects: 133
Study 36796647 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 133